Karch André, Hermann Peter, Ponto Claudia, Schmitz Matthias, Arora Amandeep, Zafar Saima, Llorens Franc, Müller-Heine Annika, Zerr Inga
Epidemiological and Statistical Methods (ESME), Department of Epidemiology, Helmholtz Centre for Infection Research, Braunschweig, Germany; National Reference Center for TSE, Clinical Dementia Center, University Medical School Göttingen, Göttingen, Germany; German Center for Infection Research (DZIF), Hannover, Germany.
National Reference Center for TSE, Clinical Dementia Center, University Medical School Göttingen, Göttingen, Germany.
Neurobiol Aging. 2015 May;36(5):1964-8. doi: 10.1016/j.neurobiolaging.2015.01.021. Epub 2015 Feb 7.
The molecular subtype of sporadic Creutzfeldt-Jakob disease (sCJD) is an important prognostic marker for patient survival. However, subtype determination is not possible during lifetime. Because the rate of disease progression is associated with the molecular subtype, this study aimed at investigating if total tau, a marker of neuronal death, allows premortem diagnosis of molecular subtype when codon 129 genotype is known. Two hundred ninety-six sCJD patients were tested for their cerebrospinal fluid total tau level at the time of diagnosis and were investigated for their sCJD subtype postmortem. There was a significant association between tau levels and the prion protein type in patients with codon 129 MM (p < 0.001), MV (p = 0.004), and VV (p = 0.001) genotype. Receiver operating characteristic analyses showed values of area under the curve of 0.76-0.80 for the different genotypes indicating a good diagnostic validity of the test. Total tau can be used as a diagnostic test for the assessment of prion protein type when codon 129 genotype is known. It provides valuable information for physicians and next of kin about the further course of disease.
散发性克雅氏病(sCJD)的分子亚型是患者生存的重要预后标志物。然而,在患者生前无法确定其亚型。由于疾病进展速度与分子亚型相关,本研究旨在探讨当已知密码子129基因型时,神经元死亡标志物总tau是否能够在生前诊断分子亚型。对296例sCJD患者在诊断时检测其脑脊液总tau水平,并在死后调查其sCJD亚型。在密码子129为MM(p < 0.001)、MV(p = 0.004)和VV(p = 0.001)基因型的患者中,tau水平与朊蛋白类型之间存在显著关联。受试者工作特征分析显示,不同基因型的曲线下面积值为0.76 - 0.80,表明该检测具有良好的诊断效度。当已知密码子129基因型时,总tau可作为评估朊蛋白类型的诊断检测方法。它为医生和患者家属提供了关于疾病后续病程的有价值信息。